In this work, we discovered that in contrast to the clinically used CFTR modulators, Esc peptides would give particular benefit especially to CF sufferers with P. aeruginosa lung infection, by combining their antibacterial activity with a potentiating effect of CFTR. This evidence concerns the gene CFTR and cystic fibrosis.